Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

ClinicalTrials.gov ID: NCT00159666

Public ClinicalTrials.gov record NCT00159666. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo

Study identification

NCT ID
NCT00159666
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
255 participants

Conditions and interventions

Interventions

  • pregabalin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2004
Primary completion
Not listed
Completion
May 31, 2006
Last update posted
Jan 21, 2021

2004 – 2006

United States locations

U.S. sites
14
U.S. states
14
U.S. cities
14
Facility City State ZIP Site status
Pfizer Investigational Site Phoenix Arizona
Pfizer Investigational Site Little Rock Arkansas
Pfizer Investigational Site Duarte California
Pfizer Investigational Site Denver Colorado
Pfizer Investigational Site Palm Beach Gardens Florida
Pfizer Investigational Site Oak Brook Illinois
Pfizer Investigational Site Flowood Mississippi
Pfizer Investigational Site St Louis Missouri
Pfizer Investigational Site Toledo Ohio
Pfizer Investigational Site Portland Oregon
Pfizer Investigational Site Allentown Pennsylvania
Pfizer Investigational Site Houston Texas
Pfizer Investigational Site Seattle Washington
Pfizer Investigational Site Madison Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00159666, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 21, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00159666 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →